1. Home
  2. IIIV vs ALT Comparison

IIIV vs ALT Comparison

Compare IIIV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i3 Verticals Inc.

IIIV

i3 Verticals Inc.

HOLD

Current Price

$16.36

Market Cap

427.0M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.92

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIIV
ALT
Founded
2012
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
427.0M
421.5M
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
IIIV
ALT
Price
$16.36
$2.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$33.20
$17.67
AVG Volume (30 Days)
432.8K
4.4M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
0.24
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$9.05
N/A
Revenue Next Year
$8.07
N/A
P/E Ratio
$69.29
N/A
Revenue Growth
N/A
105.00
52 Week Low
$16.00
$2.56
52 Week High
$33.97
$6.44

Technical Indicators

Market Signals
Indicator
IIIV
ALT
Relative Strength Index (RSI) 28.11 48.02
Support Level N/A $2.87
Resistance Level $23.52 $3.09
Average True Range (ATR) 1.17 0.17
MACD -0.55 -0.01
Stochastic Oscillator 5.17 26.42

Price Performance

Historical Comparison
IIIV
ALT

About IIIV i3 Verticals Inc.

i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: